- Synthesis method of N-methyltyramine hydrochloride
-
The invention relates to a synthesis method of N-methyltyramine hydrochloride and belongs to the technical field of organic synthesis. The synthesis method comprises dissolving p-hydroxyphenylacetic acid in a solvent 1, adding thionyl chloride into the solution, carrying out reflux stirring for a complete reaction, cooling the product, adding the reaction solution into an aqueous solution of methylamine drop by drop, then carrying out thermal insulation stirring, filtering the mixture to obtain an intermediate, dissolving the intermediate in a solvent 2, adding a reducer into the solution at the room temperature, then adding Lewis acid into the solution in batches, carrying out heating reflux stirring overnight, after the reaction is finished, introducing the reaction solution into an acid solution, adjusting pH to 7, stirring the solution, carrying out filtration and liquid separation, feeding hydrogen chloride gas into the second layer of the solvent until the hydrogen chloride gas is saturated and pH of the solution is 1, carrying out stirring and then pumping filtration, and carrying out solid leaching and drying to obtain N-methyltyramine hydrochloride. The synthesis method has the advantages of mild reaction conditions, high conversion rate, cheap and easily available raw materials, use of cheap conventional reagents, low synthesis cost, simple and easy post-treatment, no generation of a large amount of three wastes, high product yield, high purity and good quality.
- -
-
Paragraph 0028; 0029; 0031; 0032; 0034; 0035; 0037; 0038
(2017/08/29)
-
- Quinoline or quinazoline derivatives, its preparation process and its use in medicine
-
The invention relates to a quinoline or quinazoline derivative, its preparation method and an application in medicines, specifically to new quinoline or quinazoline derivative as shown in a general formula (I) and its medicinal salt or a pharmaceutical composition containing the derivative and a preparation method thereof. The invention further relates to an application of the quinoline or quinazoline derivative and its medicinal salt or the pharmaceutical composition containing the derivative in the preparation of a therapeutic agent, especially a protein kinase inhibitor. Each substituent group in the general formula (I) has the same definition as in the specification.
- -
-
Paragraph 0334-0338
(2018/01/19)
-
- OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE
-
The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R1 represents a carbamoyl group; R2 represents a lower alkyl group; both of X1 and X2 represent CH, or any one of X1 and X2 represents a nitrogen atom and the other represents CH; a group of represents a group selected from the group consisting of a pyridinyl, a pyrazinyl, a pyrazolyl, a thiadiazolyl, a triazolyl, an isoxazolyl and a thiazolyl group; and k is zero or 1, or relates to pharmaceutically acceptable salts thereof.
- -
-
Page/Page column 31
(2010/04/06)
-
- THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS
-
The invention relates to compounds represented by Formula (I):, and to prodrugs thereof, pharmaceutically salts or solvates of said compounds or said prodrugs, wherein each of X1-X5 and R1-R5 are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).
- -
-
Page/Page column 81
(2010/02/11)
-
- Process for substituted pyridines
-
This invention relates to processes for preparing compounds of the formula (I) and to processes for preparing certain intermediates of the formula wherein R1is nitro, amino or protected amino; R2is H, fluoro, chloro CF3, n
- -
-
-
- 2-amino-pyridine intermediates for beta3-Adrenergic receptor agonists
-
The instant invention relates to intermediates of Formula II, wherein R1, R2 and R3 are as defined in the specification, and to processes for preparing such intermediates. This invention also relates to processes for prepa
- -
-
-
- BETA-ADRENERGIC AGONISTS TO REDUCE A WASTING CONDITION
-
The present invention relates to the use of certain β-adrenergic agonists to reduce a wasting condition in a mammal (e.g., human).
- -
-
-
- Combination therapy including a specific beta-3 agonist and an anorectic agent
-
This invention relates to pharmaceutical compositions and methods which have utility in treating obesity in animals and particularly in humans. The invention is particularly directed to such compositions which comprise a mixture of a compound which modifi
- -
-
-